Conall M O'Seaghdha1, Adrienne Tin2, Qiong Yang3, Ronit Katz4, Yongmei Liu5, Tamara Harris6, Brad Astor7, Josef Coresh8, Caroline S Fox9, W H Linda Kao2, Michael G Shlipak10. 1. National Heart, Lung and Blood Institute's Framingham Heart Study and the Center for Population Studies, Framingham, MA; Renal Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Department of Biostatistics, Boston University School of Public Health, Boston, MA. 4. San Francisco VA Medical Center; Departments of Medicine, Epidemiology & Biostatistics, University of California, San Francisco, CA. 5. Department of Epidemiology & Prevention, Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC. 6. Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, MD. 7. Department of Population Health Sciences, The University of Wisconsin, School of Medicine and Public Health, Madison, WI. 8. Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins University, Baltimore, MD. 9. National Heart, Lung and Blood Institute's Framingham Heart Study and the Center for Population Studies, Framingham, MA; Division of Endocrinology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 10. San Francisco VA Medical Center; Departments of Medicine, Epidemiology & Biostatistics, University of California, San Francisco, CA. Electronic address: michael.shlipak@ucsf.edu.
Abstract
BACKGROUND: Carriers of the T allele of the single-nucleotide polymorphism rs13038305 tend to have lower cystatin C levels and higher cystatin C-based estimated glomerular filtration rate (eGFRcys). Adjusting for this genetic effect on cystatin C concentrations may improve GFR estimation, reclassify cases of chronic kidney disease (CKD), and strengthen risk estimates for cardiovascular disease (CVD) and mortality. STUDY DESIGN: Observational. SETTING & POPULATION: 4 population-based cohorts: Atherosclerosis Risk in Communities (ARIC), Cardiovascular Health (CHS), Framingham Heart (FHS), and Health, Aging, and Body Composition (Health ABC) studies. PREDICTORS: We estimated the association of rs13038305 with eGFRcys and serum creatinine-based eGFR (eGFRcr) and performed longitudinal analyses of the associations of eGFRcys with mortality and cardiovascular events following adjustment for rs13038305. OUTCOMES: We assessed reclassification by genotype-adjusted eGFRcys across CKD categories: <45, 45-59, 60-89, and ≥ 90 mL/min/1.73 m(2). We compared mortality and CVD outcomes in those reclassified to a worse eGFRcys category with those unaffected. Results were combined using fixed-effect inverse-variance meta-analysis. RESULTS: In 14,645 participants, each copy of the T allele of rs13038305 (frequency, 21%) was associated with a 6.4% lower cystatin C concentration, 5.5-mL/min/1.73 m(2) higher eGFRcys, and 36% [95% CI, 29%-41%] lower odds of CKD. Associations with CVD (HR, 1.17; 95% CI, 1.14-1.20) and mortality (HR, 1.22; 95% CI, 1.19-1.24) per 10-mL/min/1.73 m(2) lower eGFRcys were similar with or without rs13038305 adjustment. 1,134 (7.7%) participants were reclassified to a worse CKD category following rs13038305 adjustment, and rates of CVD and mortality were higher in individuals who were reclassified. However, the overall net reclassification index was not significant for either outcome, at 0.009 (95% CI, -0.003 to 0.022) for mortality and 0.014 (95% CI, 0.0 to 0.028) for CVD. LIMITATIONS: rs13038305 explains only a small proportion of cystatin C variation. CONCLUSIONS: Statistical adjustment can correct a genetic bias in GFR estimates based on cystatin C in carriers of the T allele of rs13038305 and result in changes in disease classification. However, on a population level, the effects on overall reclassification of CKD status are modest. Published by Elsevier Inc.
BACKGROUND: Carriers of the T allele of the single-nucleotide polymorphism rs13038305 tend to have lower cystatin C levels and higher cystatin C-based estimated glomerular filtration rate (eGFRcys). Adjusting for this genetic effect on cystatin C concentrations may improve GFR estimation, reclassify cases of chronic kidney disease (CKD), and strengthen risk estimates for cardiovascular disease (CVD) and mortality. STUDY DESIGN: Observational. SETTING & POPULATION: 4 population-based cohorts: Atherosclerosis Risk in Communities (ARIC), Cardiovascular Health (CHS), Framingham Heart (FHS), and Health, Aging, and Body Composition (Health ABC) studies. PREDICTORS: We estimated the association of rs13038305 with eGFRcys and serum creatinine-based eGFR (eGFRcr) and performed longitudinal analyses of the associations of eGFRcys with mortality and cardiovascular events following adjustment for rs13038305. OUTCOMES: We assessed reclassification by genotype-adjusted eGFRcys across CKD categories: <45, 45-59, 60-89, and ≥ 90 mL/min/1.73 m(2). We compared mortality and CVD outcomes in those reclassified to a worse eGFRcys category with those unaffected. Results were combined using fixed-effect inverse-variance meta-analysis. RESULTS: In 14,645 participants, each copy of the T allele of rs13038305 (frequency, 21%) was associated with a 6.4% lower cystatin C concentration, 5.5-mL/min/1.73 m(2) higher eGFRcys, and 36% [95% CI, 29%-41%] lower odds of CKD. Associations with CVD (HR, 1.17; 95% CI, 1.14-1.20) and mortality (HR, 1.22; 95% CI, 1.19-1.24) per 10-mL/min/1.73 m(2) lower eGFRcys were similar with or without rs13038305 adjustment. 1,134 (7.7%) participants were reclassified to a worse CKD category following rs13038305 adjustment, and rates of CVD and mortality were higher in individuals who were reclassified. However, the overall net reclassification index was not significant for either outcome, at 0.009 (95% CI, -0.003 to 0.022) for mortality and 0.014 (95% CI, 0.0 to 0.028) for CVD. LIMITATIONS: rs13038305 explains only a small proportion of cystatin C variation. CONCLUSIONS: Statistical adjustment can correct a genetic bias in GFR estimates based on cystatin C in carriers of the T allele of rs13038305 and result in changes in disease classification. However, on a population level, the effects on overall reclassification of CKD status are modest. Published by Elsevier Inc.
Authors: Daniel E Weiner; Hocine Tighiouart; Manish G Amin; Paul C Stark; Bonnie MacLeod; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2004-05 Impact factor: 10.121
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Jane Marsh; Lesley A Stevens; John W Kusek; Frederick Van Lente Journal: Clin Chem Date: 2007-03-01 Impact factor: 8.327
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Michael G Shlipak; Ronit Katz; Mark J Sarnak; Linda F Fried; Anne B Newman; Catherine Stehman-Breen; Stephen L Seliger; Brian Kestenbaum; Bruce Psaty; Russell P Tracy; David S Siscovick Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Adrienne Tin; Brad C Astor; Eric Boerwinkle; Ron C Hoogeveen; Josef Coresh; W H Linda Kao Journal: Nephrol Dial Transplant Date: 2013-01-16 Impact factor: 5.992
Authors: Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: M Kyla Shea; Kathryn Barger; Sarah L Booth; Gregory Matuszek; Mary Cushman; Emelia J Benjamin; Stephen B Kritchevsky; Daniel E Weiner Journal: Am J Clin Nutr Date: 2020-06-01 Impact factor: 7.045
Authors: Gearoid M McMahon; Matthias Olden; Maija Garnaas; Qiong Yang; Xuan Liu; Shih-Jen Hwang; Martin G Larson; Wolfram Goessling; Caroline S Fox Journal: J Am Soc Nephrol Date: 2014-05-29 Impact factor: 10.121
Authors: Josef Coresh; Lesley A Inker; Yingying Sang; Jingsha Chen; Tariq Shafi; Wendy S Post; Michael G Shlipak; Lisa Ford; Kelli Goodman; Regis Perichon; Tom Greene; Andrew S Levey Journal: Nephrol Dial Transplant Date: 2019-05-01 Impact factor: 5.992
Authors: Cyril Cyrus; Shahanas Chathoth; Chittibabu Vatte; Nafie Alrubaish; Othman Almuhanna; J Francis Borgio; Samir Al-Mueilo; Fahd Al Muhanna; Amein K Al Ali Journal: Int J Nephrol Date: 2019-08-22
Authors: Martin Magnusson; John Molvin; Gunnar Engström; Patrik Svensson-Färbom; Margaretha Persson; Anders Christensson; Peter Nilsson; Olle Melander Journal: PLoS One Date: 2016-05-24 Impact factor: 3.240